Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 4

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Classical hematology 2Breast 2Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 461Neoplasms 378Carcinoma, Non-Small-Cell Lung 354Prostatic Neoplasms 294Colorectal Neoplasms 257Lung Neoplasms 225Multiple Myeloma 206Neoplasm Metastasis 164Pancreatic Neoplasms 156Leukemia, Myeloid, Acute 153Ovarian Neoplasms 136Squamous Cell Carcinoma of Head and Neck 130Melanoma 116Carcinoma, Renal Cell 103Stomach Neoplasms 102Carcinoma, Hepatocellular 100Recurrence 98Lymphoma 94Precursor Cell Lymphoblastic Leukemia-Lymphoma 92Head and Neck Neoplasms 91Lymphoma, Non-Hodgkin 86Glioblastoma 85Brain Neoplasms 84Hematologic Neoplasms 83Urinary Bladder Neoplasms 82Triple Negative Breast Neoplasms 81Endometrial Neoplasms 80Lymphoma, Large B-Cell, Diffuse 79Leukemia, Lymphocytic, Chronic, B-Cell 77Uterine Cervical Neoplasms 74

Interventions

durvalumab 2Tretinoin 2Paclitaxel 2Carboplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1talazoparib 1sarilumab 1pexidartinib 1pertuzumab 1pembrolizumab 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1dostarlimab 1cemiplimab 1abemaciclib 1Trastuzumab 1Standard of Care 1STA 9090 1SGN-LIV1A 1Pemetrexed 1MK 2206 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Pathologic Complete Response × 30 days × Clear all
NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07586813 2026-05-14

N01-A-PICIT-GI

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
Classical hematologyGastrointestinal

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡